PortfoliosLab logoPortfoliosLab logo
PTGX vs. AXGN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PTGX vs. AXGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Protagonist Therapeutics Inc (PTGX) and AxoGen, Inc. (AXGN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PTGX achieves a 48.72% return, which is significantly higher than AXGN's 20.65% return.


PTGX

1D
-1.16%
1M
18.32%
6M
61.86%
YTD
48.72%
1Y
145.08%
3Y*
82.84%
5Y*
23.69%
10Y*

AXGN

1D
-2.69%
1M
-8.16%
6M
25.17%
YTD
20.65%
1Y
232.13%
3Y*
64.82%
5Y*
13.66%
10Y*
19.02%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PTGX vs. AXGN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PTGX
Protagonist Therapeutics Inc
48.72%126.27%68.34%110.17%-68.10%69.64%185.96%4.75%-67.64%-5.41%
AXGN
AxoGen, Inc.
20.65%98.60%141.29%-31.56%6.51%-47.65%0.06%-12.43%-27.81%214.44%

Correlation

The correlation between PTGX and AXGN is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.28

Correlation (All Time)
Calculated using the full available price history since Aug 11, 2016

0.23

The correlation between PTGX and AXGN shifts across timeframes, from 0.12 (1 year) to 0.28 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

PTGX:

$8.35B

AXGN:

$2.10B

EPS

PTGX:

-$1.74

AXGN:

-$0.65

PS Ratio

PTGX:

484.08

AXGN:

7.98

PB Ratio

PTGX:

13.97

AXGN:

8.32

Total Revenue (TTM)

PTGX:

$17.70M

AXGN:

$238.11M

Gross Profit (TTM)

PTGX:

$17.32M

AXGN:

$178.61M

EBITDA (TTM)

PTGX:

-$127.71M

AXGN:

$5.69M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PTGX vs. AXGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PTGX
PTGX Risk / Return Rank: 9797
Overall Rank
PTGX Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
PTGX Sortino Ratio Rank: 9696
Sortino Ratio Rank
PTGX Omega Ratio Rank: 9595
Omega Ratio Rank
PTGX Calmar Ratio Rank: 9898
Calmar Ratio Rank
PTGX Martin Ratio Rank: 9797
Martin Ratio Rank

AXGN
AXGN Risk / Return Rank: 9898
Overall Rank
AXGN Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
AXGN Sortino Ratio Rank: 9898
Sortino Ratio Rank
AXGN Omega Ratio Rank: 9696
Omega Ratio Rank
AXGN Calmar Ratio Rank: 9999
Calmar Ratio Rank
AXGN Martin Ratio Rank: 9999
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PTGX vs. AXGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Protagonist Therapeutics Inc (PTGX) and AxoGen, Inc. (AXGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PTGXAXGNDifference
Sharpe ratioReturn per unit of total volatility

-1.38

Sortino ratioReturn per unit of downside risk

-0.62

Omega ratioGain probability vs. loss probability

1.48

1.55

-0.07

Calmar ratioReturn relative to maximum drawdown

8.91

12.11

-3.20

Martin ratioReturn relative to average drawdown

20.77

40.79

-20.02

PTGX vs. AXGN - Sharpe Ratio Comparison

The current PTGX Sharpe Ratio is 2.86, which is lower than the AXGN Sharpe Ratio of 4.25. The chart below compares the historical Sharpe Ratios of PTGX and AXGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PTGX vs. AXGN - Drawdown Comparison

The maximum PTGX drawdown since its inception was -85.79%, smaller than the maximum AXGN drawdown of -98.49%. Use the drawdown chart below to compare losses from any high point for PTGX and AXGN.


Loading charts...

Drawdown Indicators


PTGXAXGNDifference

Max Drawdown

Largest peak-to-trough decline

-85.79%

-98.49%

+12.70%

Max Drawdown (1Y)

Largest decline over 1 year

-16.38%

-19.30%

+2.92%

Max Drawdown (3Y)

Largest decline over 3 years

-33.88%

-59.66%

+25.78%

Max Drawdown (5Y)

Largest decline over 5 years

-85.79%

-82.29%

-3.50%

Max Drawdown (10Y)

Largest decline over 10 years

-93.54%

Current Drawdown

Current decline from peak

-7.78%

-29.36%

+21.58%

Average Drawdown

Average peak-to-trough decline

-40.37%

-64.77%

+24.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.01%

5.72%

+1.29%

Volatility

PTGX vs. AXGN - Volatility Comparison

The current volatility for Protagonist Therapeutics Inc (PTGX) is 11.70%, while AxoGen, Inc. (AXGN) has a volatility of 14.73%. This indicates that PTGX experiences smaller price fluctuations and is considered to be less risky than AXGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PTGXAXGNDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.70%

14.73%

-3.03%

Volatility (6M)

Calculated over the trailing 6-month period

30.59%

34.87%

-4.28%

Volatility (1Y)

Calculated over the trailing 1-year period

51.11%

55.16%

-4.05%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.25%

64.27%

+20.98%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

90.51%

62.15%

+28.36%

Dividends

PTGX vs. AXGN - Dividend Comparison

Neither PTGX nor AXGN has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PTGX vs. AXGN - Financials Comparison

This section allows you to compare key financial metrics between Protagonist Therapeutics Inc and AxoGen, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
61.46M
(PTGX) Total Revenue
(AXGN) Total Revenue
Values in USD except per share items

Frequently Asked Questions


PTGX and AXGN have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AXGN has higher volatility (14.73%) compared to PTGX (11.70%). In terms of maximum drawdown, PTGX dropped -85.79% vs AXGN's -98.49%.

AXGN currently has the higher Sharpe Ratio (4.25 vs 2.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PTGX and AXGN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer